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Abstract: Hepatitis C virus (HCV) is a leading cause of liver disease
worldwide. With 170 million individuals infected and current
interferon-based treatment having toxic side effects and marginal
efﬁcacy, more effective antivirals are crucially needed. Although
HCV protease inhibitors were just approved by the US Food and
Drug Administration (FDA), optimal HCV therapy, analogous to
HIV therapy, will probably require a combination of antivirals tar-
geting multiple aspects of the viral lifecycle. Viral entry represents
a potential multifaceted target for antiviral intervention; however,
to date, FDA-approved inhibitors of HCV cell entry are unavailable.
Here we show that the cellular Niemann–Pick C1-like 1 (NPC1L1)
cholesterol uptake receptor is an HCV entry factor amendable to
therapeutic intervention. Speciﬁcally, NPC1L1 expression is neces-
sary for HCV infection, as silencing or antibody-mediated blocking
of NPC1L1 impairs cell culture-derived HCV (HCVcc) infection
initiation. In addition, the clinically available FDA-approved
NPC1L1 antagonist ezetimibe potently blocks HCV uptake in vitro
via a virion cholesterol-dependent step before virion–cell mem-
brane fusion. Moreover, ezetimibe inhibits infection by all major
HCV genotypes in vitro and in vivo delays the establishment of
HCV genotype 1b infection in mice with human liver grafts. Thus,Journal of Hepatology 20
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by Elsevier B.V. All rights reserved.Although clinical licensing of protease inhibitors in combina-
tion with pegylated interferon-alpha and ribavirin has markedly
improved the treatment outcome, viral resistance and adverse
effects still remain important challenges. HCV entry is the ﬁrst step
of virus–hepatocyte interaction and is not only required to initiate
infection, but is also necessary for spread and maintenance of
infection. Host entry factors are attractive complementary antivi-
ral targets since theymay increase the genetic barrier to viral resis-
tance. HCV particles in patient sera circulate in complexes with
host lipoproteins as lipoviral particles, which are enriched in tri-
glycerides, cholesterol, and several apolipoproteins [1,2]. HCV
uptake into hepatocytes requires a well characterized set of cellu-
lar binding and entry factors including glycosaminoglycans (GAG),
scavenger receptor BI (SR-BI), CD81, claudin-1 (CLDN1), occludin
(OCLN), and receptor tyrosine kinases (RTKs) (Fig. 1) (reviewed
in [3]). CD81-mediated HCV entry is furthermore dependent on
membrane cholesterol content and fusion of HCV pseudoparticles
(HCVpp) with liposomes is enhanced by cholesterol enrichment of
the target membrane [4,5]. Also, production of HCV particles is
dependent on cholesterol metabolism using the very-low-density
lipoprotein (VLDL) assembly factors microsomal transfer protein,
apolipoprotein B, and apolipoprotein E [6]. Together, these data
indicate that the HCV life cycle is intrinsically tied to hepatocyte
cholesterol metabolism.
In this context, a recent letter in Nature Medicine published by
Susan Uprichard’s laboratory at the University of Illinois-Chicago
provides additional evidence for this entanglement [7]. In this
study, the authors identiﬁed theNiemann–Pick C1-like 1 (NPC1L1)
cholesterol absorption receptor as a novel HCV entry factor and a
potential target for therapeutic intervention. The authors demon-
strated that NPC1L1 expression is necessary for cell culture-
derived HCV (HCVcc) cell entry, using both RNAi to knockdown
NPC1L1 and a blocking antibody which binds to the cholesterol
transporting large extracellular loop 1 of NPC1L1. Using the clini-
cally licensed NPC1L1 antagonist, ezetimibe, the authors inhibited12 vol. 57 j 215–217
Fig. 1. Potential functional role of Niemann–Pick C1-like 1 (NPC1L1) cholesterol absorption receptor within the HCV entry based on the ﬁndings of Sainz et al. [7].
The majority of NPC1L1 is localized on the apical canalicular surface of polarized hepatocytes reabsorbing free cholesterol excreted into bile by ABCG5/8 transporters.
Cholesterol levels are also maintained by high-density lipoprotein (HDL) and low-density lipoprotein (LDL) metabolism via scavenger receptor BI (SR-BI) and LDL receptor
(LDLR). As a bloodborne pathogen, initial HCV–hepatocyte binding to glycosaminoglycans (GAG) is presumed to be localized at the basolateral domain of polarized
hepatocytes with entry being mediated by SR-BI, CD81, claudin-1 (CLDN1), occludin (OCLN), and receptor tyrosine kinases (RTKs) that promote CD81–CLDN1 association
and membrane fusion. NPC1L1 could promote HCV entry either directly by interaction with the cholesterol of lipoviral particles or indirectly by modulating cholesterol
homeostasis and thus membrane composition required for HCV entry and membrane fusion. Ezetimibe is an inhibitor of NPC1L1 function.
International HepatologyHCV infection of all major HCV genotypes in vitro. Comparing the
effects of ezetimibe onHCVparticleswith varying cholesterol con-
tent, the study provides evidence for a cholesterol-dependent
function of NPC1L1 on HCV entry, probably in a post-binding step.
Furthermore, the authors showed efﬁcacy of ezetimibe in an HCV
animal model, demonstrating a functional role of therapeutic tar-
geting of NPC1L1 for HCV entry.
The results of this study are relevant for our understanding of
the molecular mechanism of HCV entry in the context of choles-
terol homeostasis. Based on an experiment comparing the sus-
ceptibility of HCVpp and HCVcc entry to ezetimibe, the authors
demonstrated that the cholesterol content of viral particles corre-
late with NPC1L1-mediated infection. Since ezetimibe treatment
inhibits entry of HCVcc (high cholesterol content) but not HCVpp
(low cholesterol content) the results suggest direct interaction of
NPC1L1 with the cholesterol of the viral envelope. But the impli-
cations of this study on the molecular mechanisms of cholesterol-
dependent HCV entry must also be discussed in context of cell
polarity, since Huh7 cells do not fully polarize in cell culture.
In vivo, the majority of NPC1L1 is localized at the canalicular sur-
face of hepatocytes and reabsorbs free cholesterol excreted into
bile by ABCG5/8 transporters (Fig. 1) [8]. This localization is sep-216 Journal of Hepatology 201arated by tight junction complexes from the putative site of HCV–
cell interaction on the basolateral surface of hepatocytes [3], sug-
gesting that in polarized cells, NPC1L1 may act indirectly by mod-
ulating cholesterol levels. Since biliary secretion is the only route
of cholesterol catabolism and export, NPC1L1 plays a critical role
in whole body cholesterol homeostasis [8]. Ezetimibe inhibits
NPC1L1 activity, diminishing absorption of dietary and biliary
cholesterol thereby effectively lowering serum cholesterol levels.
The use of cholesterol diminishing statin drugs prior to pegylated
interferon treatment appears to be associated with a higher sus-
tained virological response [9]. However, the interplay between
cholesterol metabolism and HCV infection is complex since low
cholesterol levels are associated with non-response to pegylated
interferon treatment, and atorvastatin treatment alone does not
alter HCV levels [9]. Thus, it is conceivable that the cholesterol
lowering effect of ezetimibe in uPA/SCID mice grafted with
human hepatocytes may modulate HCV infection.
Beyond the mechanistic data, this paper offers an interesting
clinical impact since ezetimibe has been approved as adjunct to
dietary measures during treatment of hypercholesterolaemia. In
this study, the authors show data supporting a role of NPC1L1 as
an antiviral target since pretreatment with ezetimibe delayed2 vol. 57 j 215–217
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the establishment of HCV infection in mice and resulted in partial
protection against HCV infection. Nevertheless, the use of ezetim-
ibe may have certain limitations since the antiviral dose in vitro is
100-fold above the maximal plasma concentration reached in
patients. Thus, it should be carefully evaluatedwhether increasing
ezetimibe plasma concentrations also increases liver toxicity as
has been reported in some cases [10].
Taken together, the key ﬁnding of this study is the discovery
that cholesterol metabolism plays an important role for the
HCV entry process and that targeting NPC1L1 and cholesterol
homeostasis adds a new perspective for novel antiviral strategies
targeting HCV infection.
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